Actos pioglitazone: Post-marketing study data

In the double-blind, U.S. CHICAGO study in 462 patients, pioglitazone had less progression

Read the full 137 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE